{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349374","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2026-08-13T20:36:03+00:00","discovered_at":"2026-08-13T20:37:00.269764+00:00","generated_at":"2026-08-13T20:37:30.387868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tempest Q2 net loss $5.2M; TPST-4003 collaboration with Senlang, first dosing Q4 2026","bullets":["Q2 net loss $5.2M ($0.34/share) vs $7.9M ($2.07) year ago; cash $0.8M at June 30.","Collaboration with Senlang Biotechnology for TPST-4003 in vivo CAR-T; first dosing expected Q4 2026, data H1 2027.","TPST-2003 trials: 100% complete response in 15 CAR-T-naive evaluable patients; no Grade ≥3 CRS/ICANS.","Appointed Drake Richey and John Yee to board; Andrew Fang as Head of Business Development.","Warrant inducement raised ~$2M gross proceeds; H1 cash used in ops $10.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349374","json":"https://secwatch.observer/filing/0001193125-26-349374.json","markdown":"https://secwatch.observer/filing/0001193125-26-349374.md","text":"https://secwatch.observer/filing/0001193125-26-349374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/0001193125-26-349374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/tpst-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:37:30.387868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}